Dare Bioscience, Inc. Common Stock
$0.78
$0.04 (+4.88%)
$0.77Day Range$0.81
Key Statistics
Market Cap
$15.43M
Shares Outstanding
19.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 10, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$0.79
Day High
$0.81
Day Low
$0.77
Volume
229.2K
VWAP
$0.78
Prev Close
$0.75
Transactions
--
Acc. Volume
--
About Dare Bioscience, Inc. Common Stock
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
PHARMACEUTICAL PREPARATIONSSIC 283424 employees3655 NOBEL DRIVE, SAN DIEGO, CA, 92122858-926-7655IPO Apr 10, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001401914
- Composite FIGI
- BBG001J2P362
- Share Class FIGI
- BBG001V0GDP9
- Ticker Root
- DARE
- SIC Code
- 2834
About Dare Bioscience, Inc. Common Stock (DARE) Stock
Dare Bioscience, Inc. Common Stock (DARE) closed the 2026-09-18 session at $0.78, up 4.88% versus the previous close (+0.04). The stock opened at $0.79 and traded between $0.77 and $0.81 during that session. Session trading volume was 229K shares. The volume-weighted average price (VWAP) is $0.78.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Dare Bioscience, Inc. Common Stock has a market capitalization of $15.4 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. DARE is listed on the XNAS exchange. The company employs approximately 24 people. Dare Bioscience, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2014-04-10.
On this page you can find market DARE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.